2023-2024 BORN Annual Report
The 2023-2024 year has been exceptionally busy for BORN as we led several key provincial initiatives aimed at facilitating and improving care.
One of our significant efforts has been preparing for the provincial implementation of Fetal Blood Group Genotyping (FBGG) testing. This year's report explains how these innovative tests for RhD-negative pregnancies work and how they can enhance care quality and system efficiency.
Another major focus this year has been Respiratory Syncytial Virus (RSV) surveillance. According to Ontario Health models, the Ministry of Health’s expanded RSV prevention program could reduce infant RSV hospitalizations by 83% and decrease hospital stays by 37%. Read More...
Highlight Reel
Protecting Infants from Respiratory Syncytial Virus (RSV)
Imagine reducing RSV-related hospital admissions by 83% and Pediatric Intensive Care Unit (PICU) admissions by 76%. With a new prevention program in Ontario, this could become a reality.
Learn about BORN's pivotal role in RSV surveillance and read about an Ottawa family’s experience with this virus that nearly claimed their son's life. Read more...
Paediatric Diabetes Registry
Over 7,000 children and youth in Ontario are living with diabetes - they deserve equitable, quality care.
In this video, a Paediatric Endocrinologist, a BORN Clinical Content Specialist, and a 19-year-old living with diabetes share information, timelines, and perspectives about BORN's Paediatric Diabetes Registry.
Ontario's New Blood Tests for RhD Negative Pregnancies
Learn about new tests that will make patient care more precise and the health system more efficient.
This new screening will allow for the continued prevention of hemolytic disease of the fetus and newborn (HDFN) - a potentially life-threatening disease - while reducing unnecessary health-care utilization. Prenatal Screening Ontario (PSO) is at the forefront of this initiative. Read More...
Preeclampsia Screening
Taking low-dose aspirin can prevent up to 90% of early-onset, severe preeclampsia.
But most pregnant people in Canada do not have access to preeclampsia screening and a large majority are not offered low-dose aspirin when indicated. In this video, Dr. Nan Okun, Maternal Fetal Medicine Specialist, and Alicia St. Hill, BORN Director, talk about the impact of preeclampsia, the challenges of implementing a screening program, and the next steps.
Safe Administration of Oxytocin (a High-Alert Medication)
Hear about Recommendations for the Safe Administration of Oxytocin developed by the Provincial Council of Maternal and Child Health (PCMCH), indicators developed by BORN to understand the use of oxytocin and clinical outcomes, and clinicians who have implemented the recommendations and improved policies and protocols.
Data in Action
Health Equity Journey
Numbers to Know
Improvements
Focus on Quality
Financial Information
BORN 2023-2024 Revenue
Percentage | FundingSource |
---|---|
99.2% | Ministry of Health |
0.8% | Ministry of Children, Community and Social Services |
BORN 2023-2024 Expenditures
Percentage | Funding Source |
---|---|
45.0% | Program Costs |
6.5% | Purchased Services (Tech, Legal, Privacy, Professional Services) |
6.0% | Technical Infrastructure & Maintenance |
7.5% | Prenatal Screening Ontario |
8.3% | Fetal Blood Group Genotyping (FBGG) |
25.8% | Non Invasive Prenatal Testing (NIPT) |
0.8% | Strategic Projects (Ministry of Children, Community, and Social Services) |